ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Expanded Access to Epcoritamab
- Conditions
- Lymphoma
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT05692050
A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT05686980
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 252203, Anaheim, California, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 252241, Las Vegas, Nevada, United States
An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT05669794
- Locations
- 🇫🇷
Hopital Pitie Salpetriere /ID# 253464, Paris, Ile-de-France, France
🇫🇷CHU nord - hopital Felix Guyon /ID# 250694, St Denis, Le Reunion, France
🇫🇷Centre Hospitalier Saint-Nazaire /ID# 251200, Saint-Nazaire, Loire-Atlantique, France
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
- Conditions
- Migraine
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 391
- Registration Number
- NCT05653986
- Locations
- 🇺🇸
Montefiore/Albert Einstein /ID# 252243, Bronx, New York, United States
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
- Conditions
- Chronic Idiopathic Constipation (CIC)Functional Constipation (FC)
- Interventions
- Drug: Placebo for Linaclotide
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 123
- Registration Number
- NCT05652205
- Locations
- 🇺🇸
G & L Research, LLC /ID# 250658, Foley, Alabama, United States
🇺🇸Velocity Clinical Research Phoenix /ID# 266280, Phoenix, Arizona, United States
🇺🇸HealthStar Research of Hot Springs PLLC /ID# 249481, Hot Springs, Arkansas, United States
A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections
- Conditions
- Facial LinesFacial Corrections
- Interventions
- Drug: BOTOX®/VISTABEL®Device: Juvéderm® VOLBELLA® with LidocaineDevice: Juvéderm® VOLIFT® with LidocaineDevice: Juvéderm® VOLUMA® with Lidocaine
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 73
- Registration Number
- NCT05647551
- Locations
- 🇦🇺
Dermatology Institute of Victoria /ID# 244786, South Yarra, Victoria, Australia
🇧🇪Centre de la fontaine /ID# 244763, Gerpinnes, Hainaut, Belgium
🇦🇺Eastern Plastic Surgery /ID# 244785, Box Hill North, Victoria, Australia
A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease
- Conditions
- Alzheimer's Disease DementiaHealthy Participants
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT05644977
- Locations
- 🇺🇸
Cypress, California, Cypress, California, United States
🇺🇸San Diego, California, San Diego, California, United States
🇺🇸Hialeah, Florida, Hialeah, Florida, United States
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
- Conditions
- Chronic Lymphocytic LeukemiaB Cell MalignanciesNon-Hodgkin's LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05618028
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre /ID# 246538, Madrid, Spain
🇺🇸University of California Los Angeles /ID# 246357, Los Angeles, California, United States
🇺🇸Yale University School of Medicine /ID# 259081, New Haven, Connecticut, United States
An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT05616871
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Nice - Hôpital Pasteur /ID# 252536, Nice CEDEX 1, Alpes-Maritimes, France
🇫🇷Infirmerie Protestante /ID# 252075, Caluire Et Cuire, Rhone, France
🇫🇷Cabinet libéral du Dr PAUPIERE /ID# 252604, Peronne, Somme, France
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05609630
- Locations
- 🇺🇸
New York Medical College /ID# 253437, Valhalla, New York, United States
🇺🇸Levine Children's Hospital /ID# 253491, Charlotte, North Carolina, United States
🇺🇸Randall Children's Hospital /ID# 251829, Portland, Oregon, United States